Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding.

ABSTRACT: This study evaluated effectiveness and safety of apixaban versus warfarin among venous thromboembolism patients at high-risk of bleeding (defined as having at least one of the following bleeding risk factors: ≥75 years; used antiplatelet, NSAIDs, or corticosteroids; had prior gastrointestinal bleeding or gastrointestinal-related conditions; late stage chronic kidney disease). Adult venous thromboembolism patients initiating apixaban or warfarin with ≥1 bleeding risk factor were identified from Medicare and four commercial claims databases in the United States. To balance characteristics between apixaban and warfarin patients, stabilized inverse probability treatment weighting was conducted. Cox proportional hazards models were used to estimate the risk of recurrent venous thromboembolism,

SUBMITTER: Cohen AT 

PROVIDER: S-EPMC9506658 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature